Clinical Therapeutics

Editorial comment
pp. 329-329(1)
Author: Walson P.D.

Therapeutic drug monitoring of immunosuppressant drugs in clinical practice
pp. 330-350(21)
Authors: Kahan B.D.; Keown P.; Levy G.A.; Johnston A.

Caspofungin: An echinocandin antifungal agent
pp. 351-377(27)
Authors: Stone E.A.; Fung H.B.; Kirschenbaum H.L.

Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records
pp. 378-396(19)
Authors: Boyle P.J.; King A.B.; Olansky L.; Marchetti A.; Lau H.; Magar R.; Martin J.

Treatment patterns and associated symptom improvement during six months of care for overactive bladder: A prospective, observational study
pp. 397-408(12)
Authors: Boone T.B.; Kusek J.W.; Nyberg L.M.; Steele G.; Pashos C.; Grossman M.; Diokno A.; Bull S.; Albrecht D.

Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model
pp. 409-416(8)
Authors: D'Arienzo P.A.; Leonardi A.; Bensch G.

Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial
pp. 417-433(17)
Authors: Miner C.; Brown E.; McCray S.; Gonzales J.; Wohlreich M.

Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: A prospective, randomized, double-blind study versus intramuscular ceftriaxone
pp. 434-444(11)
Authors: Legua P.; Lema J.; Moll J.; Jiang Q.; Woods G.; Friedland I.

A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model
pp. 445-456(12)
Authors: Abelson M.B.; Kaplan A.P.

''Managing'' care: We can't have it all
pp. 458-459(2)
Author: Coons S.J.

Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy
pp. 460-467(8)
Authors: Melikian C.; White T.J.; Vanderplas A.; Dezii C.M.; Chang E.

Dear Dr. Walson:
pp. 468-469(2)
Author: Schoors D.

The authors reply
pp. 469-470(2)
Authors: Arellano F.M.; Zhao S.Z.; Reynolds M.W.; Lefkowith J.; Whelton A.